GENE ONLINE|News &
Opinion
Blog

2020-12-13| Asia-PacificCOVID-19

Indonesia Receives 1.2 Million COVID-19 Vaccines from China’s Sinovac

by Tyler Chen
Share To

As the pandemic worsened, major players in the vaccine race have begun to shift focus on the logistics side of mass vaccination while hitting the gas on clinical trials and regulatory approvals. On the other hand, governments worldwide are managing to outsource vaccines and also encourage the process of local vaccine development.

On December 7th, Indonesia received 1.2 million COVID-19 vaccines from China’s Sinovac Biotech (Sinovac), with another 1.8 million doses expected to arrive in the first month of 2021, according to the President of Indonesia Joko Widodo.

 

Vaccine Challenges in Indonesia

As of December 7th, Indonesia is reported to have 569,707 cases and 17,589 deaths of COVID-19, making it one of the most infected southeast Asia countries. Without a doubt, Indonesia has a burning need for vaccines, but as the largest archipelagic state in the world and located in a tropical area, its geographic situation might cause more challenges with respect to vaccine transport, storage, cost, and time.

Based on the released data from China, CoronaVac can be stored at 2°C to 8°C for up to 3 years. In the Phase 1/2 clinical trials, CoronaVac expressed over 90% of seroconversion rates in patients of 18 to 59-year-old and above 60-year-old with no serious vaccine-related adverse events.

 

Priority for Frontline Health Workers

Indonesia plans to prioritize the health workers, police, military, and public servants for vaccination, which requires around 3 million doses. The next in line are18 to 59-year-old civilians with no comorbidities, which needs about 246 million doses.

CoronaVac is still under review for EUA from Indonesia’s food and drug agency (BPOM) which will analyze the interim results of Phase 3 clinical trial data of CoronaVac conducted in Indonesia enrolling 1,620 patients. Penny Lukito, the Head of the Food and Drug Control Agency said CoronaVac is estimated to obtain EUA in the third week of January.

 

CoronaVac Manufactured by State Pharmaceutical Firm

Besides the 3 million vaccines, Indonesia will secure raw materials to produce 15 million to 30 million doses of vaccines in the following 2 months. The ingredients will be passed on to the state pharmaceutical firm PT Bio Farma to manufacture vaccines locally, according to Joko Widodo.

 
500 Million to Boost COVID-19 Vaccine Development

In addition, Sinovac Life Sciences, a subsidiary of Sinovac, received about 500 million from Sino Biopharmaceutical on December 7 to expand R&D, manufacturing power, and capacity of COVID-19 vaccines. In exchange for the investment, Sino Biopharmaceutical will acquire approximately 15% of the total equity interest of Sinovac Life Sciences.

By Tyler Chen

Related Article: Medigen Signs Agreement with Metronic, Making it the First Taiwan-made Vaccine Deal

References
  1. https://www.reuters.com/article/us-health-coronavirus-indonesia-vaccine-idUSKBN28G0KJ
  2. https://www.bloomberg.com/news/articles/2020-12-06/indonesia-gets-first-batch-of-covid-vaccine-from-china-s-sinovac
  3. https://www.businesswire.com/news/home/20201206005056/en/Sinovac-Secures-Approximately-500-Million-in-Funding-for-COVID-19-Vaccine-Development/
  4. http://www.sinovac.com/?optionid=754&auto_id=912

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
R&D
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
Saudi Arabia Reveals Grand Ambition to Become a Global Biotech Powerhouse by 2040
2024-01-26
Parexel and Japanese Foundation for Cancer Research Collaborate to Boost Oncology Clinical Trials in Japan
2024-01-18
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top